Retrospective chart study.
The aim was to examine continuation of treatment of individuals with spinal cord injury including myelomeningocele and neurogenic detrusor overactivity, treated with repeated intra-detrusor Botulinum toxin A injections, and to investigate factors associated with discontinuation of treatment.
This study included 128 individuals with spinal cord injury and neurogenic detrusor overactivity, who were offered repeated Botulinum toxin A injections between 2001 and 2018. Continuation rates of the treatment were estimated using Kaplan Meier analysis. A Cox proportional hazard analysis was used to investigate factors predictive of discontinuation.
A total of 1156 treatments were performed. The median number of treatments was six (IQR 9, range 1−51), and median follow-up was 10.6 years (IQR 8.5, range 0−16.9). All urodynamic parameters changed significantly after the first treatment (p < 0.001). The continuation group had significantly higher mean maximum bladder capacity after the first injections compared with the discontinuation group, with a mean difference between the groups of 84.5 mL (95% CI 4.7–164.2) (p = 0.038). The probability of continuing treatments after 5 years was 59% (95% CI 50.0–67.8) and 50% (95% CI 40.1–59.3) after 10 years. Individuals aged 31–50 years were more likely to continue treatment compared with those aged >50 years (95% CI 0.21‒0.79) (p = 0.008). No other factors predicted discontinuation.
This long-term follow-up study showed that 50% of people with spinal cord injury starting intra-detrusor Botulinum toxin A for neurogenic detrusor overactivity are still receiving injections after 10 years.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
Nseyo U, Santiago-lastra Y. Long-term complications of the neurogenic bladder. Urol Clin North Am. 2017;44:355–66.
Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am. 2010;37:601–7.
Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil. 2001;80:916–22.
Blok B, Pannek J, Castro-Diaz D, Del Popolo G, Groen J, Hamid R et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018.
Schurch B, Stöhrer G, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum toxin-A for treating detrusor hyperreflexia in spinal cord injured patientpt 1s: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1):692–7.
Goessaert A, Everaert K. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. Exp Rev Neurother. 2012;12:763–75.
Bagi P, Biering-Sørensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004;38:495–8.
Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, et al. Reference for the 2011 revision of the international standards for neurological classification of spinal cord injury. J Spinal Cord Med. 2011;34:547–54.
Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Paraplegia 1969;7:179–92.
Biering-Sørensen F, DeVivo MJ, Charlifue S, Chen Y, New PW, Noonan V, et al. International Spinal Cord Injury Core Data Set (version 2.0)—including standardization of reporting. Spinal Cord 2017;55:759–64.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742–50.
Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131–9.
Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013;111:106–13.
Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, et al. More than 15 years of experience with intradetrusor onabotulinumtoxina injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol 2016;70:522–8.
Joussain C, Popoff M, Phé V, Evan A, Bosset PO, Pottier S, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn 2018;37:799–806.
Veeratterapillay R, Harding C, Teo L, Vesdev N, Abroaf A, Dorkin TJ, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol. 2014;21:175–8.
Rahnama’i MS, Marcelissen TAT, Brierley B, Schurch B, de Vries P. Long-term compliance and results of intravesical botulinum toxin A injections in male patients. Neurourol Urodyn 2017;36:1855–9.
Biering-Sørensen F, Craggs M, Kennelly M, Schick E, Wyndaele JJ. International lower urinary tract function basic spinal cord injury data set. Spinal Cord 2008;46:325–30.
The study was approved by the Danish data protection agency and the Danish patient safety authority. We certify that all applicable institutional and governmental regulations concerning the ethical use of data originally collected for clinical purposes were followed during the course of this research.
Conflict of interest
NK and KPH have received travel grants from Contura. ME has received honoraria and travel grants from Contura. However, Contura had no involvement in the collection, analysis, interpretation, or write up of this paper. PB and FBS have no disclosures to declare.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hebert, K.P., Klarskov, N., Bagi, P. et al. Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord 58, 675–681 (2020). https://doi.org/10.1038/s41393-019-0411-0